Calysta has partnered with Nofima to conduct large-scale trials in Atlantic salmon using Calysta’s FeedKind protein to improve feed efficiency and fish health.
FeedKind has been shown to use 77-98% less water and 98% less land than alternative ingredients such as soy or wheat proteins. In salmon, trout, and shrimp trials, it has produced equivalent growth and survival rates when compared to a conventional fishmeal diet. It provides the industry with the first scalable alternative protein requiring no wild caught fish or agricultural land, contributing to global food security.
Mari Moren, director of research at Nofima, said: “We are eager to do research on FeedKind as we believe that this may be an example of new protein sources that can contribute to a more sustainable aquaculture. Feedkind’s effect on salmon will be thoroughly tested at Nofima’s research facilities along with the effects this protein may have on the physicochemical qualities of the feed pellet.”
Allan LeBlanc, senior director and FeedKind product manager, stated: “The aquaculture industry is actively seeking new solutions to reduce costs associated with biological challenges and environmental impact. We look forward to working with Nofima, the industry’s preeminent research organization, to address these compelling market demands.”
The trials, to be designed by Nofima, will begin in early 2019.
